TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Enrollment and completion of 60 infants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of Head Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of replication-competent HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Beliefs and experiences around end of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bacterial detection rate in the peri-wound tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of nodal metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: myogenic oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in average daily movement activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Expressed Prostatic Secretions (EPS) for bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EBA2 performance at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBA2 performance at day 180
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBA2 performance at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of participants experiencing treatment-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With a Confirmed Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in depression prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prevalence of potentially inappropriate antipsychotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in falls prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prevalence of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the prevalence of physical restraints use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perihematomal edema (PHE) volume variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukaemia Free Survival (LFS)
Endpoint domain: Mortality/survival
Primary endpoint: Systematic plasmatic clearance (Cl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Questionnaire (including Rome Test)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tPSA changes in 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fPSA changes in 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iPSA changes in 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hK2 changes in 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Dose-limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Margin of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with altered cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognition change over 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inhibition of platelet activity (IPA, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in distribution, metabolism, and elimination of AZD6765
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in excretion of 14C (mass balance) in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of deleterious mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Septic Encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Critical-Illness-Polyneuropathy and -myopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with physical consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Melanin and Erythema indices change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dermoscopic features change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intratumoral concentration of CC-90010 in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hair Caliber Using Trichoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hair Density Using Trichoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Intravitreal Injection of hRPC
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) of Tapping Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive ANCAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Patient expectations of switching FVIII replacement therapy affecting lifestyle/quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall movement - accelerometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PsAID cutoff value for flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PsAID cutoff value for remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone loss measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Benefit of Analgesia Score (OBAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: late lumen loss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total percentage of strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pCR Within the Breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TIPS permeability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of the TIPS and patient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Alveolar-arterial oxygen gradient (PA-a,O2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in branched chain amino acid uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BASC2 Externalizing Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of injections in the first 24 months of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Last injection interval in the 2nd year of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correction of Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load in the nasopharynx and oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant pathological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pre-existing immunity related markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Superoxide Dismutase (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Glutathione reductase (GR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Acute Graft-versus-host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Acute Graft-versus-host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Abrasion behaviour of orthodontic surface sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety monitoring including adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cystoscopy procedure use count
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of participants no longer screening positive for PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Total antioxidant capacity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Abuse Potential
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuropathy Total Symptom Score-6 (NTSS-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effective analgesic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative analgesic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of sensory and motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical pregnancy rate per started cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants Able to Swallow Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Grade 3 or 4 Post Randomization Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Composite basket of complication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change from Baseline in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the HV-Labile to SLD or DCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Device Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: blood oxygen level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foveal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Time Spent in the Target Sensor Glucose Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in gastrointestinal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in abundance of fecal Roseburia spp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in abundance of fecal Butyryl CoA: Acetate CoA transferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in gastrointestinal microbial-derived metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of metabolic syndrome components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Leptin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reliability of Shoulder Symptom Irritability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level due to lower back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact force delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dose Limiting Toxicities of ARV-471
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of anti-tumor activity of ARV-471
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biochemical PSA control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in hepatitis steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bruise occurrence change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruise sizes change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area of Humphrey visual field sensitivity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fascial Closure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful application of disposable contact lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dynamic visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of cardiac monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete responses (CR) or partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Percent of Minocycline-Resistant Bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of moderate to severe BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in medication knowledge of anticoagulants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in health beliefs of anticoagulants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distribution and functionality of Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Reported Unlisted Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Improved in Number of HIV- Ribonucleic Acid (RNA) Copies, CD4 Count, and Not Progress in HIV Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean values of optimal PEP obtained by EIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean values of optimal TV obtained by EIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean values of optimal PEP obtained by scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean values of optimal TV obtained by scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bone density and quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fear of COVID-19 infection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Restoration of Joint Line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Barrett's Histology Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Pulse Oximeter Sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Respiratory Failure or Death
Endpoint domain: Mortality/survival
Primary endpoint: Eating restriction score (XEatR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With a Grade 2 or Higher Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Showing Partial Response and Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of positive urine tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anatomical restoration of macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with AF recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Self-reported health measures-SF12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IBM-Functional Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pediatric anesthesia emergence delirium (PAED) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-point agitation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a score of motion = 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Treatment Failure Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the number of abnormal reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With HBsAg Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunologic responses to tumor antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Pain During D&C Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac resynchronization therapy response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary outcome measure
Endpoint domain: General outcomes
Primary endpoint: Change from baseline on clinical global impression scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Average Serum Concentration (Cav) of Total ST After 6 Weeks of Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Serum Concentration (Ctrough) of ST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of retained endogenous insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Islet auto-antibody titre and positivity proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intensity ratings of perceived breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants completing at least 150 minutes of moderate-vigorous physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacoeconomic outcomes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Parenting Quality
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Scar assessment at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar assessment at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HOMA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Closure rate of the abdominal wall fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Count of Participants With MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes